Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,284,661 papers from all fields of science
Search
Sign In
Create Free Account
INK128
Known as:
INK-128
, TAK-228
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (3)
Benzoxazoles
Pyrimidines
Sapanisertib
Narrower (1)
MLN0128
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Antitumor effects of novel targeted therapies (TAK-228 and TAK-117) with high selectivity againts PI3K/AKT/mTOR pathway in bladder cancer : Defining molecular markers
Hernández Prat
,
Anna
2017
Corpus ID: 86534402
El cancer de vejiga avanzado se asocia con un mal pronostico y con opciones de tratamiento limitadas. A pesar del reciente exito…
Expand
2017
2017
Abstract OT2-01-21: Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during…
J. García-Saenz
,
E. Carrasco
,
M. Kneissl
,
F. Zohren
,
M. Martín
2017
Corpus ID: 78209033
Standard therapy for ER-positive tumors in the adjuvant and metastatic settings is antiestrogen therapy, including aromatase…
Expand
2016
2016
Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC)
J. Diamond
,
V. Borges
,
+11 authors
F. Zohren
2016
Corpus ID: 79122710
2015
2015
Abstract 1940: Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+ breast cancer resistant to trastuzumab therapy
P. De
,
Yuliang Sun
,
J. Carlson
,
Xiaoqian Lin
,
N. Dey
,
B. Leyland-Jones
2015
Corpus ID: 79392674
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Approximately 30% of HER2+ breast…
Expand
2013
2013
Abstract 69:In vitroandin vivotumor cell radiosensitization by the competitive mTOR inhibitor INK128.
T. Hayman
,
Tamalee R. Kramp
,
K. Camphausen
,
P. Tofilon
2013
Corpus ID: 72458584
Radiation-induced translational control of gene expression has been shown to be a component of the cellular radioresponse…
Expand
2012
2012
Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
Shunyou Wang
,
L. Lan
,
+15 authors
Yi Liu
2012
Corpus ID: 72485691
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Multiple agents that inhibit…
Expand
2012
2012
Abstract 2745: INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models
L. Kessler
,
Katti A. Jessen
,
+16 authors
Yi Liu
2012
Corpus ID: 75207178
Background: The mammalian target of rapamycin (mTOR), which comprises two protein complexes, TORC1 and TORC2, regulates tumor…
Expand
2011
2011
Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer
Shunyou Wang
,
Katti A. Jessen
,
+13 authors
Yi Liu
2011
Corpus ID: 71239458
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Objective: Preclinical characterization and evaluation…
Expand
2010
2010
Abstract 1668: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer
K. Jessen
,
Shunyou Wang
,
+13 authors
Yi Liu
2010
Corpus ID: 70775391
Pharmacokinetic / pharmacodynamic (PK/PD) modeling is a valuable strategy to achieve target inhibition as well as predictable and…
Expand
2010
2010
Abstract 4488: INK128: An orally active TORC1/2 kinase inhibitor demonstrates potent antitumor activity in preclinical models of renal cell carcinoma
Shunyou Wang
,
L. Kessler
,
+13 authors
Yi Liu
2010
Corpus ID: 85337695
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Anti-angiogenic agents have demonstrated promising…
Expand